Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial
Peter G. Kremsner, Rodolfo Andrés Ahuad Guerrero, Eunate Arana‐Arri, Gustavo Aroca et autres
176 citationsThe Lancet Infectious Diseases